Clearside Biomedical Inc (CLSD)
1.02
-0.03
(-2.86%)
USD |
NASDAQ |
Nov 21, 16:00
1.03
+0.01
(+0.98%)
After-Hours: 20:00
Clearside Biomedical Enterprise Value: 53.77M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 53.77M |
| November 20, 2024 | 56.04M |
| November 19, 2024 | 54.53M |
| November 18, 2024 | 53.77M |
| November 15, 2024 | 51.49M |
| November 14, 2024 | 56.04M |
| November 13, 2024 | 58.32M |
| November 12, 2024 | 60.60M |
| November 11, 2024 | 59.08M |
| November 08, 2024 | 62.87M |
| November 07, 2024 | 59.38M |
| November 06, 2024 | 57.13M |
| November 05, 2024 | 56.39M |
| November 04, 2024 | 53.40M |
| November 01, 2024 | 51.90M |
| October 31, 2024 | 52.65M |
| October 30, 2024 | 54.14M |
| October 29, 2024 | 54.89M |
| October 28, 2024 | 58.63M |
| October 25, 2024 | 58.63M |
| October 24, 2024 | 58.63M |
| October 23, 2024 | 61.25M |
| October 22, 2024 | 64.98M |
| October 21, 2024 | 75.07M |
| October 18, 2024 | 62.37M |
| Date | Value |
|---|---|
| October 17, 2024 | 62.37M |
| October 16, 2024 | 60.12M |
| October 15, 2024 | 59.38M |
| October 14, 2024 | 65.36M |
| October 11, 2024 | 69.09M |
| October 10, 2024 | 75.07M |
| October 09, 2024 | 74.33M |
| October 08, 2024 | 87.03M |
| October 07, 2024 | 94.51M |
| October 04, 2024 | 84.79M |
| October 03, 2024 | 75.82M |
| October 02, 2024 | 76.57M |
| October 01, 2024 | 76.57M |
| September 30, 2024 | 71.34M |
| September 27, 2024 | 57.34M |
| September 26, 2024 | 55.85M |
| September 25, 2024 | 54.36M |
| September 24, 2024 | 56.22M |
| September 23, 2024 | 60.33M |
| September 20, 2024 | 68.56M |
| September 19, 2024 | 66.31M |
| September 18, 2024 | 67.81M |
| September 17, 2024 | 68.18M |
| September 16, 2024 | 68.56M |
| September 13, 2024 | 62.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
6.810M
Minimum
Dec 21 2022
401.84M
Maximum
Aug 27 2021
89.34M
Average
63.07M
Median
Apr 26 2022
Enterprise Value Benchmarks
| Perspective Therapeutics Inc | -63.40M |
| Viking Therapeutics Inc | 4.823B |
| Atara Biotherapeutics Inc | -6.078M |
| Corvus Pharmaceuticals Inc | 532.81M |
| Crinetics Pharmaceuticals Inc | 4.426B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.688M |
| Revenue (Quarterly) | 1.038M |
| Total Expenses (Quarterly) | 6.972M |
| EPS Diluted (Quarterly) | -0.10 |
| Profit Margin (Quarterly) | -740.7% |
| Earnings Yield | -44.12% |
| Normalized Earnings Yield | -44.12 |